

### All-Cause Admissions and Readmissions, April 2018 Measure Review Cycle

**Standing Committee Orientation** 

Erin O'Rourke Taroon Amin Kate McQueston Miranda Kuwahara

May 8, 2018

# Welcome

### **NQF** Staff

- Project staff
  - Erin O'Rourke, Senior Director
  - Kate McQueston, MPH, Senior Project Manager
  - Miranda Kuwahara, MPH, Project Manager
  - Taroon Amin, PhD, Consultant
- NQF Quality Measurement leadership staff
  - Elisa Munthali, Senior Vice President

#### Agenda for the Call

- Standing Committee roll call
- Measure Evaluation Criteria Overview
- NQF's Prioritization Initiative
- SharePoint Overview
- Public comment
- Next steps

### **Standing Committee**

- John Bulger, DO, MBA (co-chair)
- Cristie Travis, MSHA (co-chair)
- Katherine Auger, MD, MSc
- Frank Briggs, PharmD, MPH
- Jo Ann Brooks, PhD, RN
- Mae Centeno, DNP, RN, CCRN, CCNS, ACNS-BC
- Helen Chen, MD
- Susan Craft, RN
- William Wesley Fields, MD, FACEP
- Steven Fishbane, MD
- Paula Minton Foltz, RN, MSN
- Brian Foy, MHA
- Laurent Glance, MD

- Anthony Grigonis, PhD
- Bruce Hall, MD, PhD, MBA
- Leslie Kelly Hall
- Paul Heidenreich, MD, MS, FACC, FAHA
- Karen Joynt Maddox, MD, MPH
- Sherrie Kaplan, PhD
- Keith Lind, JD, MS, BSN
- Paulette Niewczyk, PhD, MPH
- Carol Raphael, MPA
- Mathew Reidhead, MA
- Pamela Roberts, PhD, MSHA, ORT/L, SCFES, FAOTA, CPHQ
- Derek Robinson, MD, MBA, FACEP, CHCQM
- Thomas Smith, MD, FAPA

# Measure Evaluation Criteria Overview

#### NQF Measure Evaluation Criteria for Endorsement

NQF endorses measures for accountability applications (public reporting, payment programs, accreditation, etc.) as well as quality improvement.

- Standardized evaluation criteria
- Criteria have evolved over time in response to stakeholder feedback
- The quality measurement enterprise is constantly growing and evolving—greater experience, lessons learned, expanding demands for measures—and the criteria evolve to reflect the ongoing needs of stakeholders

### Major Endorsement Criteria (page 28)

- Importance to measure and report: Goal is to measure those aspects with greatest potential of driving improvements; if not important, the other criteria are less meaningful (must-pass)
- Reliability and Validity-scientific acceptability of measure properties: Goal is to make valid conclusions about quality; if not reliable and valid, there is risk of improper interpretation (must-pass)
- Feasibility: Goal is to, ideally, cause as little burden as possible; if not feasible, consider alternative approaches
- Usability and Use: Goal is to use for decisions related to accountability and improvement; if not useful, probably do not care if feasible
- Comparison to related or competing measures

# Criterion #1: Importance to Measure and Report (page 30-39)


- 1. Importance to measure and report—Extent to which the specific measure focus is evidence-based and important to making significant gains in healthcare quality where there is variation in or overall less-than-optimal performance.
  - 1a. Evidence: the measure focus is evidence-based
  - **1b. Opportunity for Improvement:** demonstration of quality problems and opportunity for improvement, i.e., data demonstrating considerable variation, or overall less-than-optimal performance, in the quality of care across providers; and/or disparities in care across population groups
  - 1c. Quality construct and rationale (composite measures only)

#### Subcriteron 1a: Evidence (page 31-37)

#### Outcome measures

- Empirical data demonstrate a relationship between the outcome and at least one healthcare structure, process, intervention, or service. If not available, wide variation in performance can be used as evidence, assuming the data are from a robust number of providers and results are not subject to systematic bias.
- Structure, process, intermediate outcome measures
  - The quantity, quality, and consistency of the body of evidence underlying the measure should demonstrate that the measure focuses on those aspects of care known to influence desired patient outcomes
    - » Empirical studies (expert opinion is not evidence)
    - » Systematic review and grading of evidence
      - Clinical Practice Guidelines variable in approach to evidence review
- For measures derived from patient (or family/parent/etc.) report
  - Evidence should demonstrate that the target population values the measured outcome, process, or structure and finds it meaningful.
  - Current requirements for structure and process measures also apply to patient-reported structure/process measures.

### Rating Evidence: Algorithm #1-page 34



# Criterion #1: Importance to measure and report Criteria emphasis is different for new vs. maintenance measures

New measures	Maintenance measures
<ul> <li>Evidence–Quantity, quality, consistency (QQC)</li> <li>Established link for process measures with outcomes</li> </ul>	DECREASED EMPHASIS: Require measure developer to attest evidence is unchanged from last evaluation; Standing Committee to affirm no change in evidence  IF changes in evidence, the Committee will evaluate as for new measures
<ul> <li>Gap-Opportunity for improvement, variation, quality of care across providers</li> </ul>	INCREASED EMPHASIS: Data on current performance, gap in care and variation

12

# Criterion #2: Reliability and Validity—Scientific Acceptability of Measure Properties (page 39-48)

Extent to which the measure, <u>as specified</u>, produces consistent (reliable) and credible (valid) results about the quality of health care delivery

#### 2a. Reliability (must-pass)


- 2a1. Precise specifications including exclusions
- 2a2. Reliability testing—data elements or measure score

#### 2b. Validity (must-pass)

- 2b1. Validity testing—data elements or measure score
- 2b2. Justification of exclusions—relates to evidence
- 2b3. Risk adjustment—typically for outcome/cost/resource use
- 2b4. Identification of differences in performance
- 2b5. Comparability of data sources/methods
- 2b6. Missing data


#### Reliability and Validity (page 40)

#### Assume the center of the target is the true score...




Reliable Not Valid

Consistent, but wrong



Neither Reliable Nor Valid

Inconsistent & wrong



Both Reliable And Valid

Consistent & correct

# Evaluating Scientific Acceptability—Key Points (page 41)


Empirical analysis to demonstrate the reliability and validity of the *measure as specified,* including analysis of issues that pose threats to the validity of conclusions about quality of care such as exclusions, risk adjustment/stratification for outcome and resource use measures, methods to identify differences in performance, and comparability of data sources/methods.

15

### Reliability Testing—Key Points (page 42)

- Reliability of the measure score refers to the proportion of variation in the performance scores due to systematic differences across the measured entities in relation to random variation or noise (i.e., the precision of the measure).
  - Example—Statistical analysis of sources of variation in performance measure scores (signal-to-noise analysis)
- Reliability of the data elements refers to the repeatability/reproducibility of the data and uses patientlevel data
  - Example –inter-rater reliability
- Consider whether testing used an appropriate method and included adequate representation of providers and patients and whether results are within acceptable norms
- Algorithm #2

#### Rating Reliability: Algorithm #2 - page 43



### Validity testing (pages 44 - 49)—Key Points (page 47)


#### Empirical testing

- Measure score assesses a hypothesized relationship of the measure results to some other concept; assesses the correctness of conclusions about quality
- Data element assesses the correctness of the data elements compared to a "gold standard"

#### Face validity

- Subjective determination by experts that the measure appears to reflect quality of care
  - » Empirical validity testing is expected at time of maintenance review; if not possible, justification is required.
  - » Requires systematic and transparent process, by identified experts, that explicitly addresses whether performance scores resulting from the measure as specified can be used to distinguish good from poor quality. The degree of consensus and any areas of disagreement must be provided/discussed.

### Rating Validity: Algorithm #3—page 48



#### Threats to Validity

- Conceptual
  - Measure focus is not a relevant outcome of healthcare or not strongly linked to a relevant outcome
- Unreliability
  - Generally, an unreliable measure cannot be valid
- Patients inappropriately excluded from measurement
- Differences in patient mix for outcome and resource use measures
- Measure scores that are generated with multiple data sources/methods
- Systematic missing or "incorrect" data (unintentional or intentional)

20

## Criterion #2: Scientific Acceptability

New measures	Maintenance measures
<ul> <li>Measure specifications are precise with all information needed to implement the measure</li> </ul>	NO DIFFERENCE: Require updated specifications
Reliability	<b>DECREASED EMPHASIS</b> : If prior testing
<ul> <li>Validity (including risk- adjustment)</li> </ul>	adequate, no need for additional testing at maintenance with certain exceptions (e.g., change in data source, level of analysis, or setting)
	Must address the questions regarding use of social risk factors in risk-adjustment approach

# Criterion #3: Feasibility (page 49)—Key Points (page 50)

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement.

3a: Clinical data generated during care process

**3b: Electronic sources** 

3c: Data collection strategy can be implemented

## Criterion #4: Usability and Use (page 50)— Key Points (page 51)

Extent to which potential audiences (e.g., consumers, purchasers, providers, policymakers) are using or could use performance results for both accountability and performance improvement to achieve the goal of high-quality, efficient healthcare for individuals or populations.

#### Use (4a) Now must-pass for maintenance measures

**4a1: Accountability and Transparency:** Performance results are used in at least one accountability application within three years after initial endorsement and are publicly reported within six years after initial endorsement.

**4a2:** Feedback by those being measured or others: Those being measured have been given results and assistance in interpreting results; those being measured and others have been given opportunity for feedback; the feedback has been considered by developers.

#### **Usability (4b)**

**4b1: Improvement:** Progress toward achieving the goal of high-quality, efficient healthcare for individuals or populations is demonstrated.

**4b2: Benefits outweigh the harms:** The benefits of the performance measure in facilitating progress toward achieving high-quality, efficient healthcare for individuals or populations outweigh evidence of unintended negative consequences to individuals or populations (if such evidence exists).

23

### Criteria #3-4: Feasibility, Usability and Use

New measures	Maintenance measures	
Feasibility		
<ul> <li>Measure feasible, including eMeasure feasibility assessment</li> </ul>	NO DIFFERENCE: Implementation issues may be more prominent	
Usability and Use		
Use: used in accountability     applications and public reporting	INCREASED EMPHASIS: Much greater focus on measure use and usefulness, including both impact and unintended consequences	
<ul> <li>Usability: impact and unintended consequences</li> </ul>		

# Criterion #5: Related or Competing Measures (page 51-52)

If a measure meets the four criteria <u>and</u> there are endorsed/new <u>related</u> measures (same measure focus <u>or</u> same target population) or <u>competing</u> measures (both the same measure focus <u>and</u> same target population), the measures are compared to address harmonization and/or selection of the best measure.

- 5a. The measure specifications are harmonized with related measures OR the differences in specifications are justified.
- 5b. The measure is superior to competing measures (e.g., is a more valid or efficient way to measure) OR multiple measures are justified.

# Updated guidance for measures that use ICD-10 coding: Fall 2017 and 2018

- Gap can be based on literature and/or data based on ICD-9 or ICD-10 coding
- Submit updated ICD-10 reliability testing if available; if not, testing based on ICD-9 coding will suffice
- Submit updated validity testing
  - Submit updated empirical validity testing on the ICD-10 specified measure, if available
  - OR face validity of the ICD-10 coding scheme plus face validity of the measure score as an indicator of quality
  - OR face validity of the ICD-10 coding scheme plus score-level empirical validity testing based on ICD-9 coding
  - OR face validity of the ICD-10 coding scheme plus data element level validity testing based on ICD-9 coding, with face validity of the measure score as an indicator of quality due at annual update

26

#### **eMeasures**

- "Legacy" eMeasures
  - Beginning September 30, 2017 all respecified measure submissions for use in federal programs will be required to meet the same evaluation criteria as respecified measures—the "BONNIE testing only" option will no longer meet endorsement criteria
- For all eMeasures: reliance on data from structured data fields is expected; otherwise, unstructured data must be shown to be both reliable and valid

27

#### Social Risk Factor Initiative 2.0

NQF Board approved a new 3-year initiative, where NQF will continue to allow the inclusion of social risk factors in outcome measures.

#### Through the continuation of the SDS Trial, NQF will:

- Identify preferred methodologies to link the conceptual basis for adjustment with the analyses to support it
- Develop guidance for measure developers
- Explore alternative data sources and provide guidance to the field on how to obtain and use advanced social risk factors data
- Evaluate risk models for appropriate social and clinical factors
- Explore the impact of social risk adjustment on reimbursement and access to care

#### Implement Social Risk Factor Initiative 2.0

#### As part of the continuation of the SDS Trial, NQF will:

- Continue to consider if an outcome measure includes the appropriate social and clinical factors in its risk model
- Convene the new Scientific Methods Panel (SMP) and Disparities Standing Committee (DSC) to provide guidance on the methodological questions that arose during the initial trial period
  - SMP role: review validity and provide guidance to the Standing Committee reviewing the measure
  - Standing Committee role: make endorsement recommendation
  - DSC role: provide oversight and guidance on disparities

#### **Evaluation Process**

- Preliminary analysis (PA): To assist the Committee evaluation of each measure against the criteria, NQF staff and Methods Panel (if applicable) will prepare a PA of the measure submission and offer preliminary ratings for each criteria.
  - The PA will be used as a starting point for the Committee discussion and evaluation
  - Methods Panel will complete review of Scientific Acceptability criterion for complex measures
- Individual evaluation: Each Committee member conducts an in-depth evaluation on all measures
  - Each Committee member will be assigned a subset of measures for which they will serve as lead discussant in the evaluation meeting.

#### **Evaluation Process**

- Measure evaluation and recommendations at the inperson/web meeting: The entire Committee will discuss and rate each measure against the evaluation criteria and make recommendations for endorsement.
- Staff will prepare a draft report detailing the Committee's discussion and recommendations
  - This report will be released for a 30-day public and member comment period
- Post-comment call: The Committee will re-convene for a post-comment call to discuss comments submitted
- Final endorsement decision by the CSAC
- Appeals (if any)

# Questions?




### **NQF** Prioritization Initiative

### NQF's Strategic Direction




Learn more about NQF's Strategic Plan at <a href="http://www.qualityforum.org/NQF">http://www.qualityforum.org/NQF</a> Strategic Direction 2016-2019.aspx

#### **NQF** Prioritization Initiative



#### **Prioritization Framework**



36

### **NQF** Measure Prioritization Criteria

#### **Prioritization Phase 1**

#### **Prioritization Phase 2**

## Outcome-focused (25%)

 Outcome measures and measures with strong link to improved outcomes and costs

#### Improvable (25%)

 Measures with demonstrated need for improvement and evidence-based strategies for doing so

# Meaningful to patients and caregivers (25%)

 Person-centered measures with meaningful and understandable results for patients and caregivers


# Support systemic and integrated view of care (25%)

 Measures that reflect care that spans settings, providers, and time to ensure that care is improving within and across systems of care


#### **Equity Focused**

• Measures that are disparities sensitive

# Prioritization will be conducted within and across portfolios




# Readmissions Portfolio Prioritization Scoring: Page One



NATIONAL QUALITY FORUM

## Readmissions Portfolio Prioritization Scoring

#### Page Two



## NQF Prioritization Initiative: What's Next?

Activity	Date
Finalize Phase 1 prioritization rubric	April 2018
Roll out at Spring 2018 Standing Committee Meetings	May-June 2018
Compile results from across Committees	June-July 2018
Measure Evaluation Annual Report Appendix	September 2018
Presentation/Update at NQF Annual Meeting	March 2019


## **Questions for Committee**

- Do the initial scoring results yield the outcomes you might have expected?
  - Are the highest and lowest impact measures scoring correctly based on the rubric?
  - Do you have any feedback on the way the rubric is generating results or suggestions for updates in future iterations?
- Survey to be sent by email following the presentation.


http://share.qualityforum.org/Projects/admissions\_re\_admissions/SitePages/Home.aspx

- Accessing SharePoint
- Standing Committee Policy
- Standing Committee Guidebook
- Measure Document Sets
- Meeting and Call Documents
- Committee Roster and Biographies
- Calendar of Meetings

#### Screen shot of homepage



- Please keep in mind:
- + and signs :



#### Measure Worksheet and Measure Information

- Measure Worksheet
  - Preliminary analysis, including eMeasure Technical Review if needed, and preliminary ratings
  - Member and Public comments
  - Information submitted by the developer
    - » Evidence and testing attachments
    - » Spreadsheets
    - » Additional documents

## **Public Comment**

## Next Steps

## **Next Steps**

Meeting	Date/Time
Spring 2018 Cycle: Readmissions measure evaluation web meeting #1 (2 hours)	Thursday, June 21, 2018, 12-2 pm EST
Spring 2018 Cycle: Readmissions measure evaluation web meeting #2 (2 hours)	Friday, June 22, 2018, 12-2 pm EST
Spring 2018 Cycle: Readmissions measure evaluation web meeting #3 (2 hours)	Tuesday, June 26, 2018, 12-2 pm EST
Spring 2018 Cycle: Readmissions measure evaluation post-meeting web meeting (2 hours)	Tuesday July 10, 2018, 12-2 pm EST
Spring 2018 Cycle: Post-comment web meeting (2 hours)	Tuesday, August 21, 2019, 11 am- 1 pm EST

## **Project Contact Info**

- Email: <u>readmissions@qualityforum.org</u>
- NQF Phone: 202-783-1300
- Project page: <u>http://www.qualityforum.org/All Cause Admissions and Readmissions.aspx</u>
- SharePoint site: <u>http://share.qualityforum.org/Projects/admissions\_read\_missions/SitePages/Home.aspx</u>

# Questions?

